Analysts have been eager to weigh in on the Healthcare sector with new ratings on Icon (ICLR – Research Report), Castle Biosciences (CSTL – Research Report) and Onconova Therapeutics (ONTX – Research Report).
Icon (ICLR)
Robert W. Baird analyst Eric Coldwell maintained a Hold rating on Icon yesterday and set a price target of $215.00. The company’s shares closed last Thursday at $188.30.
According to TipRanks.com, Coldwell is a 4-star analyst with an average return of 11.9% and a 61.3% success rate. Coldwell covers the Healthcare sector, focusing on stocks such as IQVIA Holdings, Syneos Health, and Owens & Minor.
Currently, the analyst consensus on Icon is a Hold with an average price target of $211.50, representing a 9.0% upside. In a report released today, Deutsche Bank also maintained a Hold rating on the stock with a $208.00 price target.
See today’s analyst top recommended stocks >>
Castle Biosciences (CSTL)
Canaccord Genuity analyst Max Masucci maintained a Buy rating on Castle Biosciences on February 22 and set a price target of $94.00. The company’s shares closed last Thursday at $78.64.
According to TipRanks.com, Masucci is a top 100 analyst with an average return of 90.7% and a 85.9% success rate. Masucci covers the Healthcare sector, focusing on stocks such as Guardant Health, Exact Sciences, and T2 Biosystems.
Currently, the analyst consensus on Castle Biosciences is a Strong Buy with an average price target of $83.50.
Onconova Therapeutics (ONTX)
In a report released today, Ahu Demir from Noble Financial maintained a Buy rating on Onconova Therapeutics, with a price target of $2.10. The company’s shares closed last Thursday at $1.45.
According to TipRanks.com, Demir is a 5-star analyst with an average return of 44.0% and a 53.8% success rate. Demir covers the Healthcare sector, focusing on stocks such as Lineage Cell Therapeutics, Ayala Pharmaceuticals, and PDS Biotechnology.
Currently, the analyst consensus on Onconova Therapeutics is a Moderate Buy with an average price target of $2.10.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.